Application note: LC-MS/MS method to analyse 20 amino acids
This application note outlines an LC-MS/MS method for analysing all 20 amino acids, without derivatisation, utilising the Supel™ Carbon LC column.
List view / Grid view
This application note outlines an LC-MS/MS method for analysing all 20 amino acids, without derivatisation, utilising the Supel™ Carbon LC column.
G-CON cleanroom PODs. Reliable, flexible prefabricated cleanrooms for the biopharmaceutical industry. On budget and on time.
A study shows inhaling hyaluronan is effective as a treatment for severe flares of chronic obstructive pulmonary disease (COPD).
In this 10-minute tutorial you will learn how to overcome the main challenges when selecting a medium for media fill tests or aseptic process simulations.
Update your blue dye ingress test and generate robust analytical CCI data in all stages of the product life cycle.
EPR's Victoria Rees interviews Dr Jaime Oliver Vigueras from Janssen to discuss rilpivirine, Janssen's long acting monthly injectable HIV treatment.
The pilot study will determine whether an inhaled formulation of ensifentrine can expedite the recovery of patients hospitalised with COVID-19.
Marketing authorisation in the EU has been given to Tivicay (dolutegravir) dispersible tablets to treat HIV in certain paediatric patients.
This whitepaper describes the proprietary HyperFlux™ optical spectrometer designs developed by Tornado Spectral Systems.
Under the contract, IRISYS LLC will develop a new, injectable formulation of drinabant that can rapidly and effectively reverse the symptoms of Acute Cannabinoid Overdose (ACO).
A summary of the current state of container closure integrity testing in the pharmaceutical industry.
Researchers say that their novel way to produce synthetic insulin could also be used to create at least eight other drugs.
Analysing the components of gentamicin, researchers have developed a new formulation for the antibiotic that does not cause deafness.
Despite the stringent storage conditions required for Pfizer and BioNTech’s COVID-19 vaccine, the need for a return to normal life has levelled the playing field for all candidate prophylactics against SARS-CoV-2.
AstraZeneca will begin testing whether they can improve the efficacy of AZD1222 by combining it with the Ad26 human adenoviral vector from Russia’s Sputnik V vaccine.